Johnson & Johnson Hit With $110M+ Verdict In Talcum Powder Linked To Cancer Lawsuit


Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

According to the CBS Report

Many of those lawsuits are pending in St. Louis, where the J&J has faced four prior trials, three of which resulted in $197 million verdicts against J&J and a talc supplier.

Thursday’s verdict came in a lawsuit against J&J and talc supplier Imerys Talc by Lois Slemp, a resident of Virginia who is currently undergoing chemotherapy after her ovarian cancer initially diagnosed in 2012 returned and spread to her liver.
Slemp claimed she developed cancer after four decades of using talc-containing products produced by J&J, including J&J’s Baby Powder and Shower to Shower Powder.

The jury awarded $5.4 million in compensatory damages and said J&J was 99 percent at fault while Imerys was just 1 percent. It awarded punitive damages of $105 million against J&J and $50,000 against Imerys.

“Once again we’ve shown that these companies ignored the scientific evidence and continue to deny their responsibilities to the women of America,”

Ted Meadows, a lawyer for Slemp and other plaintiffs, said in a statement.

Johnson & Johnson settlement Class Members include all consumers who bought one or more of the following “bedtime” products within the U.S., the District of Columbia or any U.S. territories,  including  Puerto  Rico,  Guam  and  the  Virgin  Islands between July 1, 2010 and Aug. 31, 2016 according to the class actions website

  • JOHNSON’S® BEDTIME® Baby Bath
  • JOHNSON’S® BEDTIME® Baby Lotion
  • JOHNSON’S® BEDTIME® Baby Moisture Wash
  • JOHNSON’S® Baby BEDTIME® Washcloths
  • JOHNSON’S®  BEDTIME® Baby Bubble Bath & Wash

The covered products must have been labeled (or advertised) as “clinically proven” to help a baby sleep better or to be used as part of a “bedtime” and/or “nighttime” routine.